Business Daily from THE HINDU group of publications
Wednesday, Sep 27, 2006

Cross Currency

Group Sites

Corporate - Alliances & Joint Ventures
Aurobindo Pharma ties up with Gilead

Our Bureau

Hyderabad , Sept. 26

Aurobindo Pharma Ltd has announced that it has entered into an agreement with the US-based pharma major Gilead Sciences to manufacture and market generic versions of their anti-retroviral brand Viread (Tenofovir disoproxil fumerate) in 95 countries under the Gilead access programme.

In a press release here on Tuesday, the company said the country's classification is rated according to the Human Development index and includes high prevalence focus countries in Africa and Asia, including India. According to the company, the licensing agreements with Gilead Sciences include a technology transfer to enable expeditious production of large volumes of high quality generic version of Tenofovir DF.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hyundai to finalise R&D centre plan in two months

Grasim's unit shut down for repairs
Pochanpalli road project fiscal closure
CESC's Budge Budge plant registers highest PLF in 2005-06
JK Paper declares 20 pc dividend
Ramco Textile unit bags safety award
Star Export House status to law firm
Sterling Biotech to acquire China facility
Bengal to hand over land to Tatas
HMSI to invest Rs 400 cr on capex
Moser Baer arm buys stake in Solaria
Alok Ind to buy 60 pc stake in Czech co Mileta
Oil India signs pact with ICSA
Aurobindo Pharma ties up with Gilead
`Blank cheque companies' enter India
Toyota-Kirloskar gearing up to launch small car
Subash Chandra and brother join UNI board

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line